Literature DB >> 6195813

Restricted replication of herpes simplex virus in human monocyte cultures: role of interferon.

K Linnavuori, T Hovi.   

Abstract

Exposure of fresh human monocytes in culture to high or moderate concentrations of herpes simplex virus (HSV) resulted in an abortive infection or in a highly restricted replication of the virus. Infectious progeny virus yields were obtained either by diluting the inoculum virus to multiplicities of 0.1-0.0001 PFU/cell, or by cultivation of the cells for a few days before exposure to the virus. Interferon was synthesized and released into the medium of monocyte cultures infected with the higher multiplicities, while the lower productive multiplicities or inoculations of HSV into mature macrophage cultures resulted in a production of only small amounts, if any, of interferon. Inhibition of the morphological differentiation of monocytes was seen in cultures infected with the higher multiplicities of HSV (m.o.i. 1.0-0.1 PFU/cell) and was not unlike that caused by exogenous interferon added into uninfected monocyte cultures. Antisera against the leukocyte interferon were able to enhance the production of infectious HSV in monocyte-macrophage cultures. These results suggest that interferon induced in monocytes by high multiplicities of HSV can prevent the productive replication of HSV. Apart from its possible direct antiviral effect interferon may cause this restriction of HSV replication by inhibiting the differentiation of host monocytes.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6195813     DOI: 10.1016/0042-6822(83)90112-5

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  12 in total

1.  The mechanism of poly I:C-induced antiviral activity in peritoneal macrophage.

Authors:  S Pyo
Journal:  Arch Pharm Res       Date:  1994-04       Impact factor: 4.946

2.  Demonstration of herpes simplex virus DNA in CSF cells by in situ hybridization for early diagnosis of herpes encephalitis.

Authors:  S Bamborschke; A Porr; M Huber; W D Heiss
Journal:  J Neurol       Date:  1990-04       Impact factor: 4.849

3.  Evaluation of macrophage antiviral activity in patients affected by neoplasia.

Authors:  R A Merendino; D Iannello; A Arena; L Bonina; V Greco; M Mesiti; S Chillemi; P Mastroeni
Journal:  Med Oncol Tumor Pharmacother       Date:  1988

4.  Infection of human peripheral blood mononuclear cells with a temperature-sensitive mutant of measles virus.

Authors:  S Vydelingum; J Ilonen; R Salonen; R Marusyk; A Salmi
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

5.  Measles virus inhibits lymphocyte proliferation in vitro by two different mechanisms.

Authors:  R Salonen; J Ilonen; A A Salmi
Journal:  Clin Exp Immunol       Date:  1989-03       Impact factor: 4.330

Review 6.  Genetic aspects of macrophage involvement in natural resistance to virus infections.

Authors:  S C Mogensen
Journal:  Immunol Lett       Date:  1985       Impact factor: 3.685

7.  Herpes Simplex Virus 1 Interaction with Myeloid Cells In Vivo.

Authors:  Maitreyi Shivkumar; Clara Lawler; Ricardo Milho; Philip G Stevenson
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

8.  Productive infection of isolated human alveolar macrophages by respiratory syncytial virus.

Authors:  J R Panuska; N M Cirino; F Midulla; J E Despot; E R McFadden; Y T Huang
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

9.  Measles virus infection of unstimulated blood mononuclear cells in vitro: antigen expression and virus production preferentially in monocytes.

Authors:  R Salonen; J Ilonen; A Salmi
Journal:  Clin Exp Immunol       Date:  1988-02       Impact factor: 4.330

10.  Differential effect of murine alpha/beta interferon transgenes on antagonization of herpes simplex virus type 1 replication.

Authors:  Peter Härle; Vanessa Cull; Martin-Paul Agbaga; Robert Silverman; Bryan R G Williams; Cassandra James; Daniel J J Carr
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.